Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page shows a new Revision: v3.5.4 tag, representing a small software update to the ClinicalTrials.gov page. This change does not modify the study content or documents.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page’s release/version indicator was incremented from “v3.5.2” to “v3.5.3,” reflecting a minor site revision rather than a change to the study record.SummaryDifference0.1%

- Check36 days agoChange DetectedSite revision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check64 days agoChange DetectedThe revision history is updated to include v3.5.0 as the latest revision and removes v3.4.3.SummaryDifference0.1%

- Check72 days agoChange DetectedThe page revision label was updated to v3.4.3, replacing the previous v3.4.2.SummaryDifference0.1%

- Check100 days agoChange DetectedThe study status was updated to Completed with actual completion dates, replacing the previous 'Active, not recruiting' status. The page revision was updated to v3.4.2 and the funding-status notice was removed.SummaryDifference0.8%

Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.